Clinical

The findings on tumor mutational burden (TMB) may fill a gap in biomarkers for patients who have non–small cell lung cancer (NSCLC).

At the 2022 annual meeting of the American Society of Hematology (ASH), customized cancer immunotherapy treatments now share the limelight with bispecific antibodies, which made news across disease states from large B-cell lymphoma to follicular lymphoma to multiple myeloma; as their name suggests, these treatments aim at 2 targets, increasing their potency against cancer.

The importance of identifying rare pathogenic mutations and genetic risk score among patients was explored in this new analysis, with goals that included reducing mortality and early disease detection.

A recent study found potential significance in PD-L1 analysis results for predicting immune treatment response in patients with advanced endometrial carcinoma.

Nonmedication COPD strategies, such as pulmonary rehabilitation, are highlighted.

Selecting appropriate inhalers based on individual characteristics and shared decision-making is crucial for optimizing care for patients with COPD.

Disease outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP) that related to inflammation and endotype specification were goals in this new study that evaluated the biomarker potential of S100A4.

Daratumumab can be an effective frontline MM treatment option.

Raymond Thertulien, MD, PhD, discusses high-risk factors for patients with MM.

Key opinion leaders discuss the role of combination therapies in the management of diabetes.

Managing hypertension is a critical aspect of diabetes disease management.

Data from the secondary analysis show that the improvements seen in health-related quality of life (HRQOL) translated into clinical improvements.

The case is believed to be just the second reported in the scientific literature.

Pediatric and adult patients with a diagnosis of spinal muscular atrophy (SMA) benefitted from nusinersen treatment in that they were able to prolong their walking time.

Patients who had non–small cell lung cancer (NSCLC) with homologous recombination gene mutations had better outcomes, although no single gene in the pathway appeared to have a causal role.

Considerations for insurance preauthorization and reauthorization are explored by a key opinion leader.

Patients and families facing a Rett syndrome diagnosis experience an array of burdens.

Drs Chitre and Weaver share their finals thoughts, highlighting key contributors to long-term outcomes for patients with major depressive disorder.

Early effective treatment strategies can have a significant impact on long-term effects for patients with MDD.

The findings include the identification of a 12-gene signature that could be used to categorize patients as high or low risk.

The researchers hypothesize that SARS-CoV-2 infection may have triggered thymic inflammation, spearheading initial expression of muscle-like epitopes and T-cell dysregulation.

The new report found no evidence that second-generation tyrosine kinase inhibitors (TKIs) were more likely to lead to Clostridioides difficile infection (CDI) in patients with lung cancer.

During 2022, the FDA approved 2 chimeric antigen receptor (CAR) T-cell therapies for use in second-line treatment, offering new treatment choices but raising the question: What options remain once a patient relapses after CAR T?

Levels of certain biomarkers of inflammation in prurigo nodularis were evaluated between patients with and without the chronic inflammatory skin disorder, with the goal of showing potential for precision medicine in prurigo nodularis.

Research presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition examined how certain patient and demographic characteristics that may be related to socioeconomic disparities impact the risk of hematological cancers; the influence of diabetes on chronic myeloid leukemia; and 2 updates on ponatinib.

A review showed lifestyle intervention was linked to a 24% reduction in type 2 diabetes (T2D) incidence among women with prior gestational diabetes, compared with standard of care.

Investigators writing in BMJ Open called for “a complete restoration of FOURIER trial data.” Amgen, the maker of evolocumab, said it stood by the data.

This study investigated the effects of antimicrobial therapy among patients with non–small cell lung cancer (NSCLC) who received immunotherapy with a checkpoint inhibitor or chemotherapy plus immunotherapy (CIT).

The panel shares insights into the evolution of treatment strategies for patients with diabetes.

A panel of experts discuss considerations in insurance coverage for the treatment of patients with diabetes.